• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular Safety of Tocilizumab versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis – a Multi‐database Cohort Study
Conclusion: This multi‐database population‐based cohort study found no evidence of an increased CV risk among RA patients who switched from a different biologic drug or tofacitinib to TCZ versus to a TNFi. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - February 27, 2017 Category: Rheumatology Authors: Seoyoung C. Kim, Daniel H. Solomon, James R. Rogers, Sara Gale, Micki Klearman, Khaled Sarsour, Sebastian Schneeweiss Tags: Full Length Source Type: research

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
ConclusionExposure to TNFi does not appear to influence the occurrence of ischemic stroke in the medium term in patients with RA. The impact on mortality after ischemic stroke remains inconclusive.
Source: Arthritis and Rheumatism - May 25, 2016 Category: Rheumatology Authors: Audrey S. L. Low, Mark Lunt, Louise K. Mercer, Kath D. Watson, William G. Dixon, Deborah P. M. Symmons, Kimme L. Hyrich Tags: Rheumatoid Arthritis Source Type: research

Association between ischaemic stroke and tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis
Conclusions: Exposure to TNFi does not appear to influence the occurrence of IS in the medium term in patients with RA. The impact on post‐IS mortality remains inconclusive. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - January 8, 2016 Category: Rheumatology Authors: Audrey S.L. Low, Mark Lunt, Louise K. Mercer, Kath D. Watson, William G. Dixon, Deborah P.M. Symmons, Kimme L. Hyrich Tags: Full Length Source Type: research

Rheumatoid Arthritis, Anti–Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative
ConclusionAmong postmenopausal women, RA was associated with 1.5–2.5‐fold higher CVD risk. CVD risk was strongly associated with CVD risk factors, joint pain severity, and inflammation, but not with anti‐CCP positivity or RF positivity.
Source: Arthritis and Rheumatism - August 26, 2015 Category: Rheumatology Authors: Rachel H. Mackey, Lewis H. Kuller, Kevin D. Deane, Brian T. Walitt, Yue‐Fang Chang, V. Michael Holers, William H. Robinson, Russell P. Tracy, Mark A. Hlatky, Charles B. Eaton, Simin Liu, Matthew S. Freiberg, Mehret Birru Talabi, Erik B. Schelbert, Larry Tags: Rheumatoid Arthritis Source Type: research

Rheumatoid arthritis, anti‐CCP positivity, and cardiovascular disease risk in the Women's Health Initiative
Conclusion: Among postmenopausal women, RA was associated with 1.5‐2.5 higher CVD risk, strongly associated with CV risk factors, joint pain severity, and inflammation, but similar for anti‐CCP+ and RF+. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - May 18, 2015 Category: Rheumatology Authors: Rachel H. Mackey, Lewis H. Kuller, Kevin D. Deane, Brian T. Walitt, Yuefang F. Chang, V. Michael Holers, William H. Robinson, Russell P. Tracy, Mark A. Hlatky, Charles Eaton, Simin Liu, Matthew S. Freiberg, Mehret Birru Talabi, Erik B. Schelbert, Larry W. Tags: Full Length Source Type: research

Disease activity in rheumatoid arthritis and the risk of cardiovascular events
Conclusions: Reduced time‐averaged disease activity in RA is associated with fewer CV events. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - March 16, 2015 Category: Rheumatology Authors: D.H. Solomon, G Reed, J.M. Kremer, J.R. Curtis, M.E. Farkouh, L.R. Harrold, M.C. Hochberg, P Tsao, J Greenberg Tags: Full Length Source Type: research